Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)

The primary objective of this trial was to assess the feasibility, toxicity profile, and antitumor activity of gemtuzumab ozogamicin (GO) combined with a chemotherapy remission-induction regimen in adults with untreated high-risk myelodysplastic syndrome (HR-MDS) or secondary acute myeloid leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales: de Witte, Theo, Suciu, Stefan, Meert, Liv, Halkes, Constantijn, Selleslag, Dominik, Bron, Dominique, Amadori, Sergio, Willemze, Roel, Muus, Petra, Baron, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604495/
https://www.ncbi.nlm.nih.gov/pubmed/26410352
http://dx.doi.org/10.1007/s00277-015-2486-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604495/
https://www.ncbi.nlm.nih.gov/pubmed/26410352
http://dx.doi.org/10.1007/s00277-015-2486-9

Ejemplares similares